HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
Open Access
- 16 December 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (1), 89-95
- https://doi.org/10.1038/sj.bjc.6604814
Abstract
Type II endometrial cancers (uterine serous papillary and clear cell histologies) represent rare but highly aggressive variants of endometrial cancer (EC). HER2 and EGFR may be differentially expressed in type II EC. Here, we evaluate the clinical role of HER2 and EGFR in a large cohort of surgically staged patients with type II (nonendometrioid) EC and compare the findings with those seen in a representative cohort of type I (endometrioid) EC. In this study HER2 gene amplification was studied by fluorescence in situ hybridisation (FISH) and EGFR expression by immunohistochemistry. Tissue microarrays were constructed from 279 patients with EC (145 patients with type I and 134 patients with type II EC). All patients were completely surgically staged and long-term clinical follow up was available for 258 patients. The rate of HER2 gene amplification was significantly higher in type II EC compared with type I EC (17 vs 1%, Pvs 46%, P=0.041). EGFR expression but not HER2 gene amplification was significantly associated with poor overall survival in patients with type II EC, (EGFR, median survival 20 vs 33 months, P=0.028; HER2, median survival 18 vs 29 months, P=0.113) and EGFR expression retained prognostic independence when adjusting for histology, stage, grade, and age (EGFR, P=0.0197; HER2, P=0.7855). We conclude that assessment of HER2 gene amplification and/or EGFR expression may help to select type II EC patients who could benefit from therapeutic strategies targeting both HER2 and EGFR.Keywords
This publication has 33 references indexed in Scilit:
- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cellsBritish Journal of Cancer, 2008
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 2008
- Racial disparities research: It's not just black and whiteGynecologic Oncology, 2006
- Targeting Tyrosine Kinases in Cancer: The Second WaveScience, 2006
- HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged PatientsJournal of Clinical Oncology, 2006
- Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorJournal of Clinical Oncology, 2004
- Her-2/neu Overexpression and Amplification in Uterine Papillary Serous CarcinomaJournal of Clinical Oncology, 2004
- Treatment of Uterine Papillary Serous Carcinoma with PaclitaxelGynecologic Oncology, 2001
- Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I–III) DiseaseGynecologic Oncology, 2001
- Significance of epidermal growth factor receptor expression in primary human endometrial cancerInternational Journal of Cancer, 1994